免疫血浆治疗重症流感的开放标签多中心2期随机研究
这项在美国29个学术医疗中心开展的随机开放标签2期试验,评估了抗流感血浆(血凝抑制抗体滴度≥1:80)联合标准治疗对重症流感住院患者的安全性和有效性。
核心结论
- 虽然血浆治疗对主要终点无显著影响,但治疗似乎安全且耐受良好。
- 一项3期随机试验正在进行以进一步评估该干预措施。
研究设计与样本
- 随机、开放标签、多中心2期试验,在美国29个学术医疗中心开展。
- 纳入住院儿童和成人(包括孕妇)重症流感A或B(定义为存在低氧血症或呼吸急促)。
- 随机分配接受两个单位(或儿科等效量)抗流感血浆联合标准治疗,对比单纯标准治疗,随访28天。
- 抗流感血浆的血凝抑制抗体滴度对感染株≥1:80。
- 2011年1月13日至2015年3月2日,筛查113例,从29个参与中心中的20个随机分配98例。
关键数值与推荐
- 主要终点:呼吸状态正常化时间(成人呼吸频率≤20次/分或儿童年龄定义阈值20-38次/分,且室内空气氧饱和度≥93%)。
- 抗流感血浆血凝抑制抗体滴度对感染株≥1:80。
临床怎么用
- 对于重症流感住院患者,抗流感血浆联合标准治疗未显著改善呼吸状态正常化,但可能减少严重不良事件。
- 该干预措施的安全性支持进一步开展3期随机试验验证其疗效。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(98例随机分配),主要终点未达到统计学显著性。
- 仅纳入美国20个中心,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza causes substantial morbidity and mortality despite available treatments. Anecdotal reports suggest that plasma with high antibody titres to influenza might be of benefit in the treatment of severe influenza. METHODS: In this randomised, open-label, multicentre, phase 2 trial, 29 academic medical centres in the USA assessed the safety and efficacy of anti-influenza plasma with haemagglutination inhibition antibody titres of 1:80 or more to the infecting strain. Hospitalised children and adults (including pregnant women) with severe influenza A or B (defined as the presence of hypoxia or tachypnoea) were randomly assigned to receive either two units (or paediatric equivalent) of anti-influenza plasma plus standard care, versus standard care alone, and were followed up for 28 days. The primary endpoint was time to normalisation of patients' respiratory status (respiratory rate of ≤20 breaths per min for adults or age-defined thresholds of 20-38 breaths per min for children) and a room air oxygen saturation of 93% or more. This study is registered with ClinicalTrials.gov, number NCT01052480. FINDINGS: Between Jan 13, 2011, and March 2, 2015, 113 participants were screened for eligibility and 98 were randomly assigned from 20 out of 29 participating sites. Of the participants with confirmed influenza (by PCR), 28 (67%) of 42 in the plasma plus standard care group normalised their respiratory status by day 28 compared with 24 (53%) of 45 participants on standard care alone (p=0·069). The hazard ratio (HR) comparing plasma plus standard care with standard care alone was 1·71 (95% CI 0·96-3·06). Six participants died, one (2%) from the plasma plus standard care group and five (10%) from the standard care group (HR 0·19 [95% CI 0·02-1·65], p=0·093). Participants in the plasma plus standard care group had non-significant reductions in days in hospital (median 6 days [IQR 4-16] vs 11 days [5-25], p=0·13) and days on mechanical ventilation (median 0 days [IQR 0-6] vs 3 days [0-14], p=0·14). Fewer plasma plus standard care participants had serious adverse events compared with standard care alone recipients (nine [20%] of 46 vs 20 [38%] of 52, p=0·041), the most frequent of which were acute respiratory distress syndrome (one [2%] vs two [4%] patients) and stroke (one [2%] vs two [4%] patients). INTERPRETATION: Although there was no significant effect of plasma treatment on the primary endpoint, the treatment seemed safe and well tolerated. A phase 3 randomised trial is now underway to further assess this intervention. FUNDING: National Institute of Allergy and Infectious Diseases, US National Institutes of Health.
引用
- Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017. PMID: 28522352. doi:10.1016/S2213-2600(17)30174-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。